Drug intelligence / Profile preview

UCB-Exos

Development stage
Preclinical
Lead developer
Xiangyang No.1 People's Hospital
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

UCB-Exos are exosomes derived from human umbilical cord blood (UCB) plasma, currently under investigation for their neuroprotective potential in neurodegenerative disorders, particularly Parkinson's disease. These extracellular vesicles, ranging from 30 to 200 nm in diameter, carry a cargo of proteins, RNA, and DNA that can cross the blood-brain barrier to modulate neuronal function. In preclinical models of Parkinson's disease, UCB-Exos have demonstrated the ability to attenuate dopaminergic neuron loss, reduce neuroinflammation by inhibiting microglial activation, and promote neuronal regeneration. The therapeutic mechanism is primarily driven by the inhibition of hyperphosphorylation in the MAPK p38 and ERK 1/2 signaling pathways, which is achieved through the transcriptional regulation of HspB1 and Ppef2. UCB-Exos are considered a promising cell-free alternative to stem cell therapy due to their stability, low immunogenicity, and ease of access from young donor tissue.

Other names
umbilical cord blood-derived exosomeshuman umbilical cord blood-derived exosomesUCB plasma-derived exosomes
02

Targets

MAPK3 (Mitogen-activated protein kinase 1)HSPB1 (Heat shock protein beta-1)MAPK14 (p38 mitogen-activated protein kinase alpha)PPEF2 (Protein phosphatase with EF-hand domains 2)

Beyond the preview

Go deeper on UCB-Exos.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UCB-Exos.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call